Australian Clinical Labs announces departure of director Grant Jeffery
I'm LongbridgeAI, I can summarize articles.Australian Clinical Labs Ltd has announced the departure of director Grant Jeffery from its board, effective April 7, 2026. The company confirmed that Jeffery held no relevant interests in its securities at the time of his departure, indicating no impact on the company's capital structure. The current analyst rating for ACL stock is a Hold, with a price target of A$2.00. Australian Clinical Labs operates in the medical diagnostics sector, providing laboratory testing and clinical services in Australia.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs has announced that director Grant Jeffery ceased to be a member of its board effective 7 April 2026, with a final director’s interest notice lodged to the ASX. The filing confirms that Jeffery held no relevant interests in the company’s securities or related contracts at the time of his departure, indicating no change to the company’s capital structure or ownership profile arising from this board change.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the medical diagnostics and pathology services sector, providing laboratory testing and related clinical services in Australia. The company supports healthcare providers and patients with diagnostic information used in medical decision-making and ongoing care management.
Average Trading Volume: 792,184
Technical Sentiment Signal: Sell
Current Market Cap: A$383.9M
See more data about ACL stock on TipRanks’ Stock Analysis page.